Rotator Cuff Tear ArthropathyNCT01778777
Safety Study of Univers® Revers Shoulder Prosthesis
A study testing Universe Reverse Prosthesis in people with Rotator Cuff Tear Arthropathy, run by Schulthess Klinik at 1 site in Switzerland.
Trial summary
The primary safety objective is to demonstrate that severe device-related complication (Serious Adverse Device Effect = SADE) occur within 2 years after prosthesis implantation at a rate of less than 2%. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rotator Cuff Tear Arthropathy
- What is being tested?
- Universe Reverse Prosthesis
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 166 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Sep 2013to 15 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient aged 18 years and over
- Patient with primary omarthrosis or secondary osteoarthritis associated with insufficiency in the centering function of the rotator cuff
- and
- Willing and able to give written informed consent to participate in the study including all follow-up examinations
Who cannot join
- Previous ipsilateral shoulder arthroplasty
- Acute shoulder trauma
- Post-traumatic secondary osteoarthritis
- Rheumatoid arthritis
- General medical contraindication to surgery
- Known hypersensitivity to the materials used
Show all 13Show fewer
- Tumour / malignoma
- Any disease process that would preclude accurate evaluation (e.g. neuromuscular, psychiatric or metabolic disorder)
- Bacterial infection at the time point of operation
- Recent history of substance abuse
- Legal incompetence
- Pregnancy or
- Participation in any other medical device or medicinal product study within the previous months that could influence the results of the present study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Safety, Function and Quality of Life in Patient With Rotator Cuff Tear Arthropathy Treated With the Univers® Revers Shoulder Prosthesis
The primary safety objective is to demonstrate that severe device-related complication (Serious Adverse Device Effect = SADE) occur within 2 years after prosthesis implantation at a rate of less than 2%. Such adverse events include (but are not limited to) revisions due to dislocation or glenoid loosening, septic arthritis and scapular fractures requiring surgical repair.
Read the detailed description
Reverse shoulder arthroplasty and its principles are still recognized today as the gold standard for treatment of degenerative arthropathy of the shoulder associated with an irreparable tear of the rotator cuff. The new Arthrex Univers® Revers Shoulder Prosthesis shows a large and narrow range of components, whether it is a stem, cup, spacer, inlay or glenosphere. Adjustment can be done in very small steps to match anatomic and biomechanic needs. The Arthrex Univers Revers Shoulder Prosthesis is the only device up to date that can be configured in two different inclination angles without any limitation in component use.
This multicentre case-series has the goal to evaluate whether patients with rotator cuff tear arthropathy benefit from the Univers® Revers shoulder prosthesis in terms of low complication risk, as well as high function and quality of life.
- Conditions
- Rotator Cuff Tear Arthropathy
- Being tested
- Universe Reverse Prosthesis
- Keywords
- rotator cuff tear arthropathy, inverse prosthesis, safety, universe reverse
- Medical subject headings
- Rotator Cuff Tear Arthropathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Universe Reverse ProsthesisDevice
Implantation of an universe reverse prosthesis
| Study group | Role | What they receive |
|---|---|---|
| UniverseReverse | Experimental | Cohort get an universe reverse prosthesis Receives: Device: Universe Reverse Prosthesis |
What is being measured
The primary outcome is the main question the study is designed to answer.
SADE within 2 years po
The primary safety objective is to demonstrate that severe device-related complication (Serious Adverse Device Effect = SADE) occur within 2 years after prosthesis implantation at a rate of less than 2%.
Measured: 2 years po
Secondary outcomes (9)
Risk of adverse events intra-operatively, and post-operatively up to 2 years follow-up
As typically one single surgery should be sufficient to treat the patient, all secondary surgical interventions should be revisions due to a complication.
The occurrence and time of revision surgery (implant survival) will be described by Kaplan-Meier curve.
Measured: 2 years
Prosthesis survival at 2, 5 and 10 years
All Patients with a prosthesis revision will be documented along with the date of revision. At each follow up time point the proportion of patients with prosthesis revision will be estimated. Time to prosthesis revision will be examined by survival methods to account for censored data.
Measured: 2, 5 and 10 years
Constant (Murley) score (CS)
The Constant (Murley) score is possibly the most commonly used tool for assessment of shoulder function. The physician asks and documents answers to QOL questions (pain and ADL, ability to work, sleep, sports and leisure) and certain clinical parameters (active ROM, abduction strength). The different scales will be summed and normalized to O=worst to 100= best. A German version is available for clinical use. Investigators are obliged to use a spring balance for the force measurements. Only one measurement per patient per assessment will be done.
Measured: 6mo, 1, 2, 5 and 10 years
The Shoulder Pain and Disability Index (SPADI)
The Shoulder Pain and Disability Index (SPADI) is a short, self-administered questionnaire that provides an item scoring by a visual analogue scale (VAS) from 0 (no pain/no difficulty, i.e. best) to 11 (worst pain imaginable/so difficult required help, i.e. worst). Five items assess pain and 8 items disability of the arm (function). The unweighted means of the 5 pain and the 8 function items will be transformed into the scale from 0 (=worst) to 100 (=best) for both scales and are used to determine pain and function scores. The average of these two scores then gives the total SPADI score. A validated German version is available.
Measured: 6mo, 1, 2, 5 and 10 years
Short version of the Disability of the Arm, Shoulder and Hand questionnaire (QuickDASH)
The Disability of the Arm, Shoulder and Hand questionnaire (DASH) is a comprehensive self-administered questionnaire about symptoms and functioning of the entire upper extremity. The DASH enquires about the ability to perform simple and complex activities of daily living (ADL) that are commonly performed with either one or both arms. The total score is derived from the unweighted mean of 30 items, of which at least 27 have to be answered. The QuickDASH is a more efficient version of the DASH outcome measure that appears to retain its measurement properties. It contains eleven items and is similar with regard to scores and properties to the full DASH. A validated full-length German version is available that can be used in the shortened version.
Measured: 6mo, 1, 2, 5 and 10 years
EuroQoL EQ-5D-5L
The EQ-5D is a widely used instrument to measure and value generic health (status). It is based on a descriptive system that defines health in terms of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. The instrument is designed for self-completion, and patients also rate their overall health on the day of the interview on a 0-100 visual analogue scale (EQ-VAS).
Measured: 6wk, 6mo, 1, 2, 5 and 10 years
Patient satisfaction
In order to obtain an overall assessment of the arthroplasty result, patients will be asked to assess their current state of health in general related to the operated shoulder joint at the follow-up compared to the state before the arthroplasty. This so-called 'transition' question has the possible answers 'much worse', 'slightly worse', 'equal', 'slightly better', and 'much better'. Patients also rate their level of satisfaction, with the help of a numeric rating scale (NRS: 0-10), in terms of how the outcome met up to their preoperative expectations of the arthroplasty. Finally, they will be asked whether - with their current knowledge of the outcome - they would again choose the operation if they found themselves in similar circumstances to those which prevailed preoperatively.
Measured: 6wk, 6mo, 1, 2, 5 and 10 years
Radiographic Parameters
Three radiographs should be taken at each study visit: AP view in internal and external rotation and axial view. The images will be collected digitally and centralized for latter evaluation by an independent reviewer based on the radiographic assessment CRF developed by the Schulthess clinic, including the following parameters:
- Scapular notching
- Signs of osteolysis at the glenoid and at the stem
- Status of tuberculum majus and minus
- Glenoid migration
- Glenoid component seating
- Stem position
- Change of relative position of components
- Ectopic bone formation
- Cortical bone resorption
- Prosthesis breakage
- Rotation failure
- Luxation of the prosthesis
- PE Wear of the metaglene
- PE Dissociation
Measured: 6mo, 1, 2, 5 and 10 years
Patient active and passive range of motion (ROM) and shoulder strength
The following active and passive range of motion parameters will be documented:
- Abduction
- Elevation
- External rotation by 0°
- External-internal rotation by 90°
Measured: 6mo, 1, 2, 5 and 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2013 (estimated)
- Study start1 Sep 2013
- Primary completion1 Jun 2019
- Study completion15 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rotator Cuff Tear ArthropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 166 participants (actual)
Sponsor and investigators
- Lead sponsor
- Schulthess Klinik
- Sponsor type
- University, hospital or other
- Collaborators
- Arthrex, Inc.
- Responsible party
- Sponsor
- Investigators
- Hans-Kaspar Schwyzer, Dr., Principal investigator, Schulthess Klinik
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01778777
- Sponsor's protocol ID
- UniversRevers
- Status last verified
- May 2022
- First submitted
- 24 Jan 2013
- Last updated
- 18 Apr 2023
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety, Function and Quality of Life in Patient With Rotator Cuff Tear Arthropathy Treated With the Univers® Revers Shoulder Prosthesis
- ClinicalTrials.gov ID
- NCT01778777
- Acronym / sponsor ID
- UniversRevers
- Conditions
- Rotator Cuff Tear Arthropathy
- Keywords
- rotator cuff tear arthropathy, inverse prosthesis, safety, universe reverse
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 166 participants (actual)
- Lead sponsor
- Schulthess KlinikUniversity, hospital or other
- Collaborators
- Arthrex, Inc.
- Study start
- 1 Sep 2013 (actual)
- Primary completion
- 1 Jun 2019 (actual)
- Study completion
- 15 Apr 2023 (actual)
- First posted
- 29 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary safety objective is to demonstrate that severe device-related complication (Serious Adverse Device Effect = SADE) occur within 2 years after prosthesis implantation at a rate of less than 2%. Such adverse events include (but are not limited to) revisions due to dislocation or glenoid loosening, septic arthritis and scapular fractures requiring surgical repair.
Detailed description
Reverse shoulder arthroplasty and its principles are still recognized today as the gold standard for treatment of degenerative arthropathy of the shoulder associated with an irreparable tear of the rotator cuff. The new Arthrex Univers® Revers Shoulder Prosthesis shows a large and narrow range of components, whether it is a stem, cup, spacer, inlay or glenosphere. Adjustment can be done in very small steps to match anatomic and biomechanic needs. The Arthrex Univers Revers Shoulder Prosthesis is the only device up to date that can be configured in two different inclination angles without any limitation in component use.
This multicentre case-series has the goal to evaluate whether patients with rotator cuff tear arthropathy benefit from the Univers® Revers shoulder prosthesis in terms of low complication risk, as well as high function and quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| UniverseReverse | Experimental | Device: Universe Reverse ProsthesisCohort get an universe reverse prosthesis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patient aged 18 years and over
- Patient with primary omarthrosis or secondary osteoarthritis associated with insufficiency in the centering function of the rotator cuff
- and
- Willing and able to give written informed consent to participate in the study including all follow-up examinations
Key exclusion criteria (13 listed)
- Previous ipsilateral shoulder arthroplasty
- Acute shoulder trauma
- Post-traumatic secondary osteoarthritis
- Rheumatoid arthritis
- General medical contraindication to surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Universe Reverse ProsthesisImplantation of an universe reverse prosthesis | Device | UniverseReverse |
Primary outcome
SADE within 2 years po
Time frame: 2 years po
The primary safety objective is to demonstrate that severe device-related complication (Serious Adverse Device Effect = SADE) occur within 2 years after prosthesis implantation at a rate of less than 2%.
9 secondary outcomes
Risk of adverse events intra-operatively, and post-operatively up to 2 years follow-up
Time frame: 2 years
Prosthesis survival at 2, 5 and 10 years
Time frame: 2, 5 and 10 years
Constant (Murley) score (CS)
Time frame: 6mo, 1, 2, 5 and 10 years
The Shoulder Pain and Disability Index (SPADI)
Time frame: 6mo, 1, 2, 5 and 10 years
Short version of the Disability of the Arm, Shoulder and Hand questionnaire (QuickDASH)
Time frame: 6mo, 1, 2, 5 and 10 years
EuroQoL EQ-5D-5L
Time frame: 6wk, 6mo, 1, 2, 5 and 10 years
Patient satisfaction
Time frame: 6wk, 6mo, 1, 2, 5 and 10 years
Radiographic Parameters
Time frame: 6mo, 1, 2, 5 and 10 years
Patient active and passive range of motion (ROM) and shoulder strength
Time frame: 6mo, 1, 2, 5 and 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2023.
Related trials for Rotator Cuff Tear Arthropathy
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Recruiting
SMR Stemless Reverse vs SMR Reverse Shoulder System
Arthroplasty, Replacement
Active, not recruiting
Lyophilized Platelet-Rich Plasma Lysate vs Dextrose Prolotherapy for Partial Rotator Cuff Tears
Rotator Cuff Tear, Rotator Cuff Syndrome
Active, not recruiting
Efficacy and Safety of Digital Therapeutics for Improving Shoulder Function After Rotator Cuff Repair
Rotator Cuff Tear Arthropathy, Repair of a Cuff Tear
RecruitingObservational study
Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block
Shoulder Surgery, Shoulder Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hans-Kaspar Schwyzer, Dr. principal investigator
Schulthess Klinik
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Universe Reverse Prosthesis in people with Rotator Cuff Tear Arthropathy, run by Schulthess Klinik at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SADE within 2 years po (time frame: 2 years po). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.